Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Vaccine Congress Draws Pharmaceutical MNCs

This article was originally published in PharmAsia News

Executive Summary

More than 300 scientists and executives from pharmaceutical MNCs congregated at the recent First World Vaccine Congress held in Guangdong, China. Participants included top officials from the International Vaccine Institute of Korea, Baxter International, Intercell and GSK, reflecting overseas companies' optimism in the country's vaccine market. The event aimed to boost the internationalization of China's vaccine industry, speeding up changes in its production and biotechnology. Although major vaccine player Baxter has not started its vaccine business in China, it has been keeping a close eye on the country and analysts believe it will enter the market soon. Baxter considers China a high-priority international market, especially for vaccine products. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel